JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Description: LY2886721 (LY 2886721; LY-2886721) is a novel, potent and selective BACE (beta-secretase) inhibitor with the potential for the treatment of AD-Alzheimer's Disease. BACE1 is a key protease controlling the formation of amyloid beta, a peptide hypothesized to play a significant role in the pathogenesis of Alzheimer's disease (AD). LY2886721 elicits robust central Abeta pharmacodynamic responses in mice, dogs, and humans. LY2886721 has high selectivity against key off-target proteases, which efficiently translates in vitro activity into robust in vivo amyloid beta lowering in nonclinical animal models.
References: J Alzheimers Dis. 2011; 24 Suppl 2:43-52; J Neurosci. 2015 Jan 21; 35(3):1199-210.
Related CAS#: 262036-49-6 (HCl )
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Compare
Add to wishlist
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!